Version 1
: Received: 26 May 2020 / Approved: 27 May 2020 / Online: 27 May 2020 (04:54:08 CEST)
Version 2
: Received: 3 June 2020 / Approved: 4 June 2020 / Online: 4 June 2020 (04:07:01 CEST)
Version 3
: Received: 5 June 2020 / Approved: 7 June 2020 / Online: 7 June 2020 (17:21:49 CEST)
How to cite:
Suravajhala, R.; Parashar, A.; Malik, B.; Nagaraj, A.V.; Padmanaban, G.; Kavi Kishor, P.; Polavarapu, R.; Suravajhala, P. Comparative Docking Studies on Curcumin with COVID-19 Proteins. Preprints2020, 2020050439. https://doi.org/10.20944/preprints202005.0439.v1
Suravajhala, R.; Parashar, A.; Malik, B.; Nagaraj, A.V.; Padmanaban, G.; Kavi Kishor, P.; Polavarapu, R.; Suravajhala, P. Comparative Docking Studies on Curcumin with COVID-19 Proteins. Preprints 2020, 2020050439. https://doi.org/10.20944/preprints202005.0439.v1
Suravajhala, R.; Parashar, A.; Malik, B.; Nagaraj, A.V.; Padmanaban, G.; Kavi Kishor, P.; Polavarapu, R.; Suravajhala, P. Comparative Docking Studies on Curcumin with COVID-19 Proteins. Preprints2020, 2020050439. https://doi.org/10.20944/preprints202005.0439.v1
APA Style
Suravajhala, R., Parashar, A., Malik, B., Nagaraj, A.V., Padmanaban, G., Kavi Kishor, P., Polavarapu, R., & Suravajhala, P. (2020). Comparative Docking Studies on Curcumin with COVID-19 Proteins. Preprints. https://doi.org/10.20944/preprints202005.0439.v1
Chicago/Turabian Style
Suravajhala, R., Rathnagiri Polavarapu and Prashanth Suravajhala. 2020 "Comparative Docking Studies on Curcumin with COVID-19 Proteins" Preprints. https://doi.org/10.20944/preprints202005.0439.v1
Abstract
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a respiratory syndrome caused by positive RNA virus resulting in outbreak of corona virus disease 2019 (COVID-19). The SARS-CoV-2 genome and its association to SAR-CoV-1 vary from ca. 66% to 96% depending on the type of betacoronavirdeae family members. With several drugs, viz. chloroquine, hydroxychloroquine, ivermectin, quinidine, artemisinin, remdesivir, azithromycin considered for clinical trials, there has been an inherent need to find distinctive antiviral mechanisms of these drugs. On the other hand, curcumin, a natural bioactive molecule has been shown to have a therapeutic potential for various diseases, but no role of it in COVID-19 has been explored. In this work, we show the binding potential of curcumin targeted to a host of SARS-CoV-2 proteins, viz. spike glycoproteins (PDB ID: 6VYB), nucleocapsid phosphoprotein (PDB ID: 6VYO), membrane glycoprotein (PDB ID: 6M17) along with nsp10 (PDB ID: 6W4H) and RNA dependent RNA polymerase (PDB ID: 6M71) structures. Our results indicate that curcumin has potential antiviral protein binding affinity towards SARS-CoV-2 proteins which is comparable with other repurposed drugs that are considered for clinical trials.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
